Your browser doesn't support javascript.
loading
Opportunities and challenges for newborn screening and early diagnosis of rare diseases in Latin America.
Giugliani, Roberto; Castillo Taucher, Silvia; Hafez, Sylvia; Oliveira, Joao Bosco; Rico-Restrepo, Mariana; Rozenfeld, Paula; Zarante, Ignacio; Gonzaga-Jauregui, Claudia.
Afiliación
  • Giugliani R; Department of Genetics UFRGS, Medical Genetics Service HCPA, DASA and Casa dos Raros, Porto Alegre, Brazil.
  • Castillo Taucher S; Clinical Geneticist, Hospital Clínico Universidad de Chile, Clínica Alemana de Santiago, Santiago, Chile.
  • Hafez S; The NOA Project, Panama City, Panama.
  • Oliveira JB; Laboratório de Genética Molecular, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
  • Rico-Restrepo M; Americas Health Foundation, Bogota, Colombia.
  • Rozenfeld P; Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP), UNLP, CONICET, asociado CIC PBA, Facultad de Ciencias Exactas, Departamento de Ciencias Biológicas, La Plata, Argentina.
  • Zarante I; Instituto de Genética Humana, Pontificia Universidad Javeriana, Bogotá, Colombia.
  • Gonzaga-Jauregui C; International Laboratory for Human Genome Research, Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Juriquilla, México.
Front Genet ; 13: 1053559, 2022.
Article en En | MEDLINE | ID: mdl-36568372
Rare diseases (RDs) cause considerable death and disability in Latin America. Still, there is no consensus on their definition across the region. Patients with RDs face a diagnostic odyssey to find a correct diagnosis, which may last many years and creates a burden for caregivers, healthcare systems, and society. These diagnostic delays have repercussions on the health and economic burden created by RDs and continue to represent an unmet medical need. This review analyzes barriers to the widespread adoption of newborn screening (NBS) programs and early diagnostic methods for RDs in Latin America and provides recommendations to achieve this critical objective. Increasing the adoption of NBS programs and promoting early diagnosis of RDs are the first steps to improving health outcomes for patients living with RDs. A coordinated, multistakeholder effort from leaders of patient organizations, government, industry, medical societies, academia, and healthcare services is required to increase the adoption of NBS programs. Patients' best interests should remain the guiding principle for decisions regarding NBS implementation and early diagnosis for RDs.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Guideline / Screening_studies Idioma: En Revista: Front Genet Año: 2022 Tipo del documento: Article País de afiliación: Brasil

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Guideline / Screening_studies Idioma: En Revista: Front Genet Año: 2022 Tipo del documento: Article País de afiliación: Brasil